Clinical outcomes of single‐fraction stereotactic radiation therapy of lung tumors
BACKGROUND The objective of the current study was to investigate the effects and the morbidities of single‐fraction stereotactic radiation therapy (SRT) for lung tumors. METHODS A Microtron device was modified to deliver stereotactic irradiation under respiratory gating. Between August 1998 and Dece...
Gespeichert in:
| Veröffentlicht in: | Cancer 2006-03, Vol.106 (6), p.1347-1352 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1352 |
|---|---|
| container_issue | 6 |
| container_start_page | 1347 |
| container_title | Cancer |
| container_volume | 106 |
| creator | Hara, Ryusuke Itami, Jun Kondo, Tatsuya Aruga, Takashi Uno, Takashi Sasano, Nakashi Ohnishi, Kayoko Kiyozuka, Makoto Fuse, Masashi Ito, Masashi Naoi, Kuniji Kohno, Yuzuru |
| description | BACKGROUND
The objective of the current study was to investigate the effects and the morbidities of single‐fraction stereotactic radiation therapy (SRT) for lung tumors.
METHODS
A Microtron device was modified to deliver stereotactic irradiation under respiratory gating. Between August 1998 and December 2004, 59 malignant lung tumors (11 primary tumors, 48 metastases) that measured < 40 mm in greatest dimension were treated by single‐fraction SRT. Nine tumors received a minimal dose of < 30 grays (Gy), and 50 tumors received a minimal dose of ≥ 30 Gy. The macroscopic target volume ranged from 1 cc to 19 cc (mean, 5 cc).
RESULTS
The 1‐year and 2‐year local progression‐free rates (LPFRs) were 93% and 78%, respectively. The overall survival rate was 76.5% at 1 year and 41% at 2 years. Local regrowth of the irradiated tumor was a direct cause of death in two patients. Only the minimal radiation dose to the reference target volume tended to have an influence on the LPFR (P = 0.068). The 2‐year LPFRs for patients who received irradiation doses of ≥ 30 Gy and < 30 Gy were 83% and 52%, respectively. With regard to morbidities, Grade 3 respiratory symptoms (according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme) were noted in one patient.
CONCLUSIONS
The results from the current study suggested that single‐fraction SRT was tolerable and was capable of attaining excellent local control in patients who had malignant lung tumors that measured < 4 cm in greatest dimension. Cancer 2006. © 2006 American Cancer Society.
The authors investigated the effects and morbidities of single‐fraction stereotactic radiation therapy (SRT) for lung tumors. The results suggested that single‐fraction SRT was tolerable and was capable of attaining excellent local control in patients who had malignant lung tumors smaller than 4 cm in greatest dimension. |
| doi_str_mv | 10.1002/cncr.21747 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811886501</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1811886501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4927-1014e5e3a6ac4a422e1bda58f44dc6a89115a2e13926aefef1714b4668e6f97d3</originalsourceid><addsrcrecordid>eNp9kMtKxTAQhoMoerxsfADpRhChmkmTJl1K8QaiIAruSk461UjbHJMWOTsfwWf0Scy5gDtXwz98c-Ej5BDoGVDKzk1v_BkDyeUGmQAtZEqBs00yoZSqVPDsZYfshvAeo2Qi2yY7kHMpQNAJeSpb21uj28SNg3EdhsQ1SbD9a4s_X9-N12awrk_CgB7dsEgm8bq2etke3tDr2Xwx0479azKMnfNhn2w1ug14sK575Pnq8qm8Se8erm_Li7vU8ILJFOKbKDDTuTZcc8YQprUWquG8NrlWBYDQsZkVLNfYYAMS-JTnucK8KWSd7ZGT1d6Zdx8jhqHqbDDYtrpHN4YKFIBSuaAQ0dMVarwLwWNTzbzttJ9XQKuFxWphsVpajPDReu847bD-Q9faInC8BnSI7qKl3tjwx0mhmAAVOVhxn7bF-T8nq_K-fFwd_wVcuYuh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811886501</pqid></control><display><type>article</type><title>Clinical outcomes of single‐fraction stereotactic radiation therapy of lung tumors</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Hara, Ryusuke ; Itami, Jun ; Kondo, Tatsuya ; Aruga, Takashi ; Uno, Takashi ; Sasano, Nakashi ; Ohnishi, Kayoko ; Kiyozuka, Makoto ; Fuse, Masashi ; Ito, Masashi ; Naoi, Kuniji ; Kohno, Yuzuru</creator><creatorcontrib>Hara, Ryusuke ; Itami, Jun ; Kondo, Tatsuya ; Aruga, Takashi ; Uno, Takashi ; Sasano, Nakashi ; Ohnishi, Kayoko ; Kiyozuka, Makoto ; Fuse, Masashi ; Ito, Masashi ; Naoi, Kuniji ; Kohno, Yuzuru</creatorcontrib><description>BACKGROUND
The objective of the current study was to investigate the effects and the morbidities of single‐fraction stereotactic radiation therapy (SRT) for lung tumors.
METHODS
A Microtron device was modified to deliver stereotactic irradiation under respiratory gating. Between August 1998 and December 2004, 59 malignant lung tumors (11 primary tumors, 48 metastases) that measured < 40 mm in greatest dimension were treated by single‐fraction SRT. Nine tumors received a minimal dose of < 30 grays (Gy), and 50 tumors received a minimal dose of ≥ 30 Gy. The macroscopic target volume ranged from 1 cc to 19 cc (mean, 5 cc).
RESULTS
The 1‐year and 2‐year local progression‐free rates (LPFRs) were 93% and 78%, respectively. The overall survival rate was 76.5% at 1 year and 41% at 2 years. Local regrowth of the irradiated tumor was a direct cause of death in two patients. Only the minimal radiation dose to the reference target volume tended to have an influence on the LPFR (P = 0.068). The 2‐year LPFRs for patients who received irradiation doses of ≥ 30 Gy and < 30 Gy were 83% and 52%, respectively. With regard to morbidities, Grade 3 respiratory symptoms (according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme) were noted in one patient.
CONCLUSIONS
The results from the current study suggested that single‐fraction SRT was tolerable and was capable of attaining excellent local control in patients who had malignant lung tumors that measured < 4 cm in greatest dimension. Cancer 2006. © 2006 American Cancer Society.
The authors investigated the effects and morbidities of single‐fraction stereotactic radiation therapy (SRT) for lung tumors. The results suggested that single‐fraction SRT was tolerable and was capable of attaining excellent local control in patients who had malignant lung tumors smaller than 4 cm in greatest dimension.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.21747</identifier><identifier>PMID: 16475150</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adenocarcinoma - radiotherapy ; Adenocarcinoma - secondary ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carcinoma, Hepatocellular - radiotherapy ; Carcinoma, Hepatocellular - secondary ; Carcinoma, Squamous Cell - radiotherapy ; Carcinoma, Squamous Cell - secondary ; Dose Fractionation ; Dose-Response Relationship, Radiation ; Female ; Humans ; Lung Neoplasms - pathology ; Lung Neoplasms - radiotherapy ; lung tumor ; Male ; Maximum Tolerated Dose ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Pneumology ; respiratory gating ; single fraction ; stereotactic radiation therapy ; Stereotaxic Techniques ; Survival Rate ; Tomography, X-Ray Computed ; Treatment Outcome ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Cancer, 2006-03, Vol.106 (6), p.1347-1352</ispartof><rights>Copyright © 2006 American Cancer Society</rights><rights>2006 INIST-CNRS</rights><rights>(c) 2006 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4927-1014e5e3a6ac4a422e1bda58f44dc6a89115a2e13926aefef1714b4668e6f97d3</citedby><cites>FETCH-LOGICAL-c4927-1014e5e3a6ac4a422e1bda58f44dc6a89115a2e13926aefef1714b4668e6f97d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.21747$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.21747$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27903,27904,45553,45554,46387,46811</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17582518$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16475150$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hara, Ryusuke</creatorcontrib><creatorcontrib>Itami, Jun</creatorcontrib><creatorcontrib>Kondo, Tatsuya</creatorcontrib><creatorcontrib>Aruga, Takashi</creatorcontrib><creatorcontrib>Uno, Takashi</creatorcontrib><creatorcontrib>Sasano, Nakashi</creatorcontrib><creatorcontrib>Ohnishi, Kayoko</creatorcontrib><creatorcontrib>Kiyozuka, Makoto</creatorcontrib><creatorcontrib>Fuse, Masashi</creatorcontrib><creatorcontrib>Ito, Masashi</creatorcontrib><creatorcontrib>Naoi, Kuniji</creatorcontrib><creatorcontrib>Kohno, Yuzuru</creatorcontrib><title>Clinical outcomes of single‐fraction stereotactic radiation therapy of lung tumors</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
The objective of the current study was to investigate the effects and the morbidities of single‐fraction stereotactic radiation therapy (SRT) for lung tumors.
METHODS
A Microtron device was modified to deliver stereotactic irradiation under respiratory gating. Between August 1998 and December 2004, 59 malignant lung tumors (11 primary tumors, 48 metastases) that measured < 40 mm in greatest dimension were treated by single‐fraction SRT. Nine tumors received a minimal dose of < 30 grays (Gy), and 50 tumors received a minimal dose of ≥ 30 Gy. The macroscopic target volume ranged from 1 cc to 19 cc (mean, 5 cc).
RESULTS
The 1‐year and 2‐year local progression‐free rates (LPFRs) were 93% and 78%, respectively. The overall survival rate was 76.5% at 1 year and 41% at 2 years. Local regrowth of the irradiated tumor was a direct cause of death in two patients. Only the minimal radiation dose to the reference target volume tended to have an influence on the LPFR (P = 0.068). The 2‐year LPFRs for patients who received irradiation doses of ≥ 30 Gy and < 30 Gy were 83% and 52%, respectively. With regard to morbidities, Grade 3 respiratory symptoms (according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme) were noted in one patient.
CONCLUSIONS
The results from the current study suggested that single‐fraction SRT was tolerable and was capable of attaining excellent local control in patients who had malignant lung tumors that measured < 4 cm in greatest dimension. Cancer 2006. © 2006 American Cancer Society.
The authors investigated the effects and morbidities of single‐fraction stereotactic radiation therapy (SRT) for lung tumors. The results suggested that single‐fraction SRT was tolerable and was capable of attaining excellent local control in patients who had malignant lung tumors smaller than 4 cm in greatest dimension.</description><subject>Adenocarcinoma - radiotherapy</subject><subject>Adenocarcinoma - secondary</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - radiotherapy</subject><subject>Carcinoma, Hepatocellular - secondary</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Carcinoma, Squamous Cell - secondary</subject><subject>Dose Fractionation</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>lung tumor</subject><subject>Male</subject><subject>Maximum Tolerated Dose</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Pneumology</subject><subject>respiratory gating</subject><subject>single fraction</subject><subject>stereotactic radiation therapy</subject><subject>Stereotaxic Techniques</subject><subject>Survival Rate</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxTAQhoMoerxsfADpRhChmkmTJl1K8QaiIAruSk461UjbHJMWOTsfwWf0Scy5gDtXwz98c-Ej5BDoGVDKzk1v_BkDyeUGmQAtZEqBs00yoZSqVPDsZYfshvAeo2Qi2yY7kHMpQNAJeSpb21uj28SNg3EdhsQ1SbD9a4s_X9-N12awrk_CgB7dsEgm8bq2etke3tDr2Xwx0479azKMnfNhn2w1ug14sK575Pnq8qm8Se8erm_Li7vU8ILJFOKbKDDTuTZcc8YQprUWquG8NrlWBYDQsZkVLNfYYAMS-JTnucK8KWSd7ZGT1d6Zdx8jhqHqbDDYtrpHN4YKFIBSuaAQ0dMVarwLwWNTzbzttJ9XQKuFxWphsVpajPDReu847bD-Q9faInC8BnSI7qKl3tjwx0mhmAAVOVhxn7bF-T8nq_K-fFwd_wVcuYuh</recordid><startdate>20060315</startdate><enddate>20060315</enddate><creator>Hara, Ryusuke</creator><creator>Itami, Jun</creator><creator>Kondo, Tatsuya</creator><creator>Aruga, Takashi</creator><creator>Uno, Takashi</creator><creator>Sasano, Nakashi</creator><creator>Ohnishi, Kayoko</creator><creator>Kiyozuka, Makoto</creator><creator>Fuse, Masashi</creator><creator>Ito, Masashi</creator><creator>Naoi, Kuniji</creator><creator>Kohno, Yuzuru</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>20060315</creationdate><title>Clinical outcomes of single‐fraction stereotactic radiation therapy of lung tumors</title><author>Hara, Ryusuke ; Itami, Jun ; Kondo, Tatsuya ; Aruga, Takashi ; Uno, Takashi ; Sasano, Nakashi ; Ohnishi, Kayoko ; Kiyozuka, Makoto ; Fuse, Masashi ; Ito, Masashi ; Naoi, Kuniji ; Kohno, Yuzuru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4927-1014e5e3a6ac4a422e1bda58f44dc6a89115a2e13926aefef1714b4668e6f97d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adenocarcinoma - radiotherapy</topic><topic>Adenocarcinoma - secondary</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - radiotherapy</topic><topic>Carcinoma, Hepatocellular - secondary</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Carcinoma, Squamous Cell - secondary</topic><topic>Dose Fractionation</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>lung tumor</topic><topic>Male</topic><topic>Maximum Tolerated Dose</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Pneumology</topic><topic>respiratory gating</topic><topic>single fraction</topic><topic>stereotactic radiation therapy</topic><topic>Stereotaxic Techniques</topic><topic>Survival Rate</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hara, Ryusuke</creatorcontrib><creatorcontrib>Itami, Jun</creatorcontrib><creatorcontrib>Kondo, Tatsuya</creatorcontrib><creatorcontrib>Aruga, Takashi</creatorcontrib><creatorcontrib>Uno, Takashi</creatorcontrib><creatorcontrib>Sasano, Nakashi</creatorcontrib><creatorcontrib>Ohnishi, Kayoko</creatorcontrib><creatorcontrib>Kiyozuka, Makoto</creatorcontrib><creatorcontrib>Fuse, Masashi</creatorcontrib><creatorcontrib>Ito, Masashi</creatorcontrib><creatorcontrib>Naoi, Kuniji</creatorcontrib><creatorcontrib>Kohno, Yuzuru</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hara, Ryusuke</au><au>Itami, Jun</au><au>Kondo, Tatsuya</au><au>Aruga, Takashi</au><au>Uno, Takashi</au><au>Sasano, Nakashi</au><au>Ohnishi, Kayoko</au><au>Kiyozuka, Makoto</au><au>Fuse, Masashi</au><au>Ito, Masashi</au><au>Naoi, Kuniji</au><au>Kohno, Yuzuru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcomes of single‐fraction stereotactic radiation therapy of lung tumors</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2006-03-15</date><risdate>2006</risdate><volume>106</volume><issue>6</issue><spage>1347</spage><epage>1352</epage><pages>1347-1352</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
The objective of the current study was to investigate the effects and the morbidities of single‐fraction stereotactic radiation therapy (SRT) for lung tumors.
METHODS
A Microtron device was modified to deliver stereotactic irradiation under respiratory gating. Between August 1998 and December 2004, 59 malignant lung tumors (11 primary tumors, 48 metastases) that measured < 40 mm in greatest dimension were treated by single‐fraction SRT. Nine tumors received a minimal dose of < 30 grays (Gy), and 50 tumors received a minimal dose of ≥ 30 Gy. The macroscopic target volume ranged from 1 cc to 19 cc (mean, 5 cc).
RESULTS
The 1‐year and 2‐year local progression‐free rates (LPFRs) were 93% and 78%, respectively. The overall survival rate was 76.5% at 1 year and 41% at 2 years. Local regrowth of the irradiated tumor was a direct cause of death in two patients. Only the minimal radiation dose to the reference target volume tended to have an influence on the LPFR (P = 0.068). The 2‐year LPFRs for patients who received irradiation doses of ≥ 30 Gy and < 30 Gy were 83% and 52%, respectively. With regard to morbidities, Grade 3 respiratory symptoms (according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme) were noted in one patient.
CONCLUSIONS
The results from the current study suggested that single‐fraction SRT was tolerable and was capable of attaining excellent local control in patients who had malignant lung tumors that measured < 4 cm in greatest dimension. Cancer 2006. © 2006 American Cancer Society.
The authors investigated the effects and morbidities of single‐fraction stereotactic radiation therapy (SRT) for lung tumors. The results suggested that single‐fraction SRT was tolerable and was capable of attaining excellent local control in patients who had malignant lung tumors smaller than 4 cm in greatest dimension.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16475150</pmid><doi>10.1002/cncr.21747</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2006-03, Vol.106 (6), p.1347-1352 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811886501 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - radiotherapy Adenocarcinoma - secondary Adult Aged Aged, 80 and over Biological and medical sciences Carcinoma, Hepatocellular - radiotherapy Carcinoma, Hepatocellular - secondary Carcinoma, Squamous Cell - radiotherapy Carcinoma, Squamous Cell - secondary Dose Fractionation Dose-Response Relationship, Radiation Female Humans Lung Neoplasms - pathology Lung Neoplasms - radiotherapy lung tumor Male Maximum Tolerated Dose Medical sciences Middle Aged Neoplasm Staging Pneumology respiratory gating single fraction stereotactic radiation therapy Stereotaxic Techniques Survival Rate Tomography, X-Ray Computed Treatment Outcome Tumors Tumors of the respiratory system and mediastinum |
| title | Clinical outcomes of single‐fraction stereotactic radiation therapy of lung tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T00%3A56%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcomes%20of%20single%E2%80%90fraction%20stereotactic%20radiation%20therapy%20of%20lung%20tumors&rft.jtitle=Cancer&rft.au=Hara,%20Ryusuke&rft.date=2006-03-15&rft.volume=106&rft.issue=6&rft.spage=1347&rft.epage=1352&rft.pages=1347-1352&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.21747&rft_dat=%3Cproquest_cross%3E1811886501%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811886501&rft_id=info:pmid/16475150&rfr_iscdi=true |